Myelofibrosis

The PBS subsidises ruxolitinib for patients with myelofibrosis (MF).

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with ruxolitinib under the National Health Act 1953, section 85 for patients with either primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis confirmed through a bone marrow biopsy report and classified as:

  • high risk and intermediate-2 risk
  • intermediate-1 risk with severe disease-related symptoms that are resistant, refractory or intolerant to available therapy.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing ruxolitinib.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised ruxolitinib to treat patients with either high risk and intermediate-2 risk or intermediate-1 risk myelofibrosis can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised ruxolitinib to treat patients with high risk and intermediate-2 risk or intermediate-1 risk myelofibrosis can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 26 September 2022